Gida Iphayan Ds8201A

Iphayan Ds8201A

A takaice bayanin:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Tuntuɓi yanzu Sanya Baron Siyayya

Cikakken Bayani

Tags samfurin

Samfurin Samfurin DS - 8201A, wanda kuma aka sani da Trastutuzumab Douruxan (t - DXD), magani ne na conjugate (ADC) wanda aka tsara don lura da ita2 - tabbatacce cutar kansa. Ya haɗu da ta2 - Targeting antambody (kama da trastuzumab) tare da mai ƙarfi propoisomase i inhiisomasarshe i inhiisrit (deruxtecan) azaman mai biya na Cytotoxic. Abubuwan da miyagun ƙwayoyi sun ba da Chemotherapy kai tsaye a cikin sel sel bayyana ta2, inganta ingancin yanayi yayin iyakance lalacewar sel na yau da kullun.

Kashi:
Cathepsdin
Abu babu .:
015200.01
Girman sashi:
50ul, 2mg / ml
Fure:
N / a
Nau'in:
N / a
Yanayin ajiya da sufuri:
Store a - 70 ° C. Bushe kankara kawo.